Lumbar Spinal Stenosis Surgery Options Compared

Lumbar spinal stenosis surgery is often spoken of as if it were one procedure with optional extras. It is not. Decompression makes room for nerves.

Fusion asks bone to join vertebrae so a level stops moving. A motion-preserving implant is a third plan, built for a narrow labeled group, not for every tight canal. Two randomized trials that added fusion to decompression did not agree. Treating them as one vote, or treating a device label as a personal invitation, is how the choice gets simpler than the evidence.

What the narrowing is, and how symptoms usually behave, is the subject of What Is Lumbar Spinal Stenosis? This article compares operations. It does not decide that you need one.

Three plans, not three sizes of one operation

Decompression removes bone and soft tissue that are crowding nerves. A laminectomy, taking the roof of the canal, is one way to do that. The vertebrae are not asked to grow together. The aim is the leg pain, heaviness, numbness, or walking limit that comes from the tight spot.

Decompression plus fusion does that nerve work and then tries to stop motion at the treated level. Bone graft is added so the vertebrae can heal into one solid bone. Screws and rods usually hold the level while the bone grows. The extra project is stability. It is a larger operation than decompression alone.

A motion-preserving implant is neither of those. It is placed after decompression and is designed to stabilize the level while still allowing some movement. One such device has an FDA label, and the label is narrow. It is not a general upgrade for stenosis, and it is not a fusion with a different logo.

People often meet these options in the wrong order. They hear “stenosis” and then hear a brand of surgery. The diagnosis explains the tight space.

It does not pick the column in the figure. A single-level tight canal in a stable spine is a different problem from a level that moves, and both are different from the specific combination written on a device label. Is a Laminectomy Alone Enough for Spinal Stenosis? stays with the fusion question. This page puts that question next to the implant question so the three plans stay visible at once.

Who the fusion trials actually enrolled

The Swedish Spinal Stenosis Study randomized 247 people, ages 50 to 80, with stenosis at one or two levels. One hundred thirty-five of them had a degenerative slip. Fusion was added to decompression and compared with decompression alone. The trial was not “fusion versus doing nothing,” and it was not limited to people with a slip.

The SLIP trial randomized 66 people ages 50 to 80 with stable grade I degenerative spondylolisthesis and stenosis. Stable means the trial was not built around an obviously loose level. The comparison was again laminectomy plus fusion versus laminectomy alone.

Those enrollment lines are the whole reason the results are allowed to disagree. A 247-person mix of one- and two-level stenosis, with and without a slip, is not a 66-person group defined by a stable grade I slip. If a consult quotes “the trial” without saying which people were in it, ask for the head count and the slip rule before you accept the moral of the story.

A slip plus stenosis is common enough to have its own explanation, in Spondylolisthesis and Spinal Stenosis Together. Having both findings does not automatically mean fusion. The trials below are what “not automatically” looks like in numbers.

Where the two trials did not agree

Both trials failed to show that fusion clearly won on the Oswestry Disability Index at two years. That questionnaire asks how back problems limit everyday activities. In the Swedish trial, fusion did not improve the disability score or walking distance at two years.

In SLIP, the disability score was not significantly different at two years. On that particular form, at that time point, adding fusion did not separate the groups in a clear way in either study.

They did not agree on other outcomes. SLIP found a larger gain on the SF-36 physical component summary, a physical-health score, at two years: 15.2 points with fusion versus 9.5 with decompression alone. The Swedish trial’s walking result did not move with fusion. A quality-of-life score and a walking distance are not interchangeable, even when both are about “function” in casual speech.

Later surgery also split. In SLIP, reoperation through four years was 14 percent after fusion and 34 percent after decompression alone. In the Swedish trial, additional spine surgery over a mean of 6.5 years was 22 percent after fusion and 21 percent after decompression alone.

One study found fewer returns to the operating room after fusion. The other found essentially the same rate. Neither percentage is a personal probability, and neither is a reason to ignore the other paper.

The size of the operation differed in a way that is easy to skip. Swedish hospital stays averaged 7.4 days with fusion and 4.1 days with decompression alone. That is an average in that trial’s hospitals, not your discharge date. It is still a real cost of the added procedure, measured in days, sitting beside outcomes that did not all move.

Read the last row on purpose. Leaving a cell blank of a number is part of the comparison. SLIP has a reoperation contrast this article can cite.

It does not, in these paragraphs, lend a hospital-stay contrast. Filling that cell with the Swedish days would be how two trials become one anecdote.

A motion-preserving implant for a narrow labeled group

Fusion stops motion on purpose. A different idea is to decompress the nerves and then implant a device meant to keep some motion. The FDA summary of the TOPS System describes that device as attached with pedicle screws after lumbar decompression, supporting load while allowing movement between its endplates, including bending and rotation.

“Designed to maintain motion” is a design sentence. It is not a measured result in you.

The labeled group is specific. The FDA says the device is for people ages 35 to 80 with degenerative spondylolisthesis up to grade I, at one level from L3 to L5, with moderate to severe lumbar stenosis, and with thickening of the ligamentum flavum, scarring of the facet capsule, or both. It is not labeled for a slip worse than grade I.

It is not labeled for slips from trauma, earlier surgery, or a condition present from birth. The same page lists further situations in which it should not be used, including a disc herniation at the surgical level, a sideways slip or a curve with a Cobb angle over 10 degrees, a body mass index over 40, bone density at a T-score of -2.0 or less, infection, and cauda equina syndrome.

That list is the label. It is not a score you can pass. Approval is not candidacy.

Sharing a diagnosis with someone inside the label does not put you inside it. Bone quality, the exact level, the grade, and whether the slip is degenerative all have to match, and even then a surgeon is making a clinical judgment the approval letter does not make for them.

The manufacturer page is not the evidence. The TOPS System page (the link goes to the manufacturer’s website) is where the company describes its device. Use the FDA summary for the indication and the exclusions.

Do not let a product page outrank the label or the trials above, which studied fusion versus decompression, not this implant versus fusion. How fusion and a motion-preserving implant are each built to behave, and what neither can promise, is set out on the fusion comparison page.

What neither a label nor a trial can decide for you

The Swedish result does not mean fusion never helps. It means that in that group, at two years, disability and walking did not improve because fusion was added, and later additional surgery was about as common either way, at the price of a longer stay. SLIP does not mean every grade I slip should be fused. It means that in 66 people with a stable grade I degenerative slip and stenosis, a physical-health score moved more with fusion, disability did not clearly separate at two years, and reoperation was less common after fusion through four years.

The implant label does not break the tie. It describes a device for a slice of the SLIP-like population, one level, grade I, degenerative, L3 to L5, inside an age band, and then it adds requirements and exclusions the trials of fusion were not written to test. If you are outside the label, the device is the wrong conversation. If you are inside the words of the label, you are in a discussion, not in a result.

Non-surgical care is still the path many people stay on, especially when walking is acceptable and weakness is not progressing. Surgery comes up when stenosis symptoms limit life enough that the trade looks reasonable. Which operation, if any, depends on whether the level moves, how wide the decompression would have to be, bone quality, other illnesses, and the symptom you rank first.

A trial can inform that list. It cannot see your imaging.

How to use the comparison in a consultation

Write the symptom in one line before you talk operations. “I can walk one block before my legs feel heavy” is a stenosis sentence, close to what the Swedish trial measured as walking. “My back pain score on a form” is closer to a disability questionnaire, which did not clearly favor fusion at two years in either trial. “I want this level to keep some motion” is a design preference, and it only becomes a device conversation if the label actually fits.

Then write the anatomy in one line. Level or levels. Whether a slip is present, what grade, and whether it is degenerative.

Whether bending films show motion. If any of those are unknown, the three columns in the first figure are still theoretical. Ask the surgeon which column they are recommending and which row of the table they are relying on.

A recommendation that cannot point to a row is a preference. Preferences can be reasonable. They should not be dressed up as the result both trials shared.

Take the disagreements in with you. Fusion did not improve disability or walking at two years in the larger stenosis trial, and it lengthened the stay. Fusion improved a physical-health score and was followed by fewer reoperations in a smaller trial limited to stable grade I degenerative slips, without a clear disability difference at two years.

An implant exists for a narrower labeled group, and the page that sells it is not the page that defines that group. That is the comparison. The decision is still a person’s anatomy and a person’s limit, not an average of the columns.